Industries > Pharma > Asthma and COPD Therapies Market Forecast 2015-2025

Asthma and COPD Therapies Market Forecast 2015-2025

Opportunities for Leading Companies

PUBLISHED: 05 October 2015
PAGES: 309
PRODUCT CODE: PHA0070
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0070 Categories: ,

Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
What can be expected from the Asthma and COPD Therapies market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
 
Our 309-page report provides 260 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and therapies
How will submarkets perform to 2025? Our study forecasts revenues in the following asthma and COPD therapies submarkets:
• Combination drugs
• Anti-inflammatory drugs
– Corticosteroids
– Anti-Leukotrienes
– Monoclonal antibodies
– Other anti-inflammatories
• Bronchodilator monotherapy
– Short-acting beta2-agonist (SABAs)
– Long-acting beta2-agonist (LABAs)
– Anticholinergics

How will individual therapies perform to 2025? Our study forecasts revenues for 27 therapies including 5 promising pipeline candidates:
• Ventolin
• ProAir
• Proventil
• Xopenex
• Foradil
• Serevent
• Arcapta/Onbrez
• Brovana
• Spiriva
• Atrovent
• Eklira/Tudorza/Bretaris
• Flixotide/Flovent
• Pulmicort
• QVAR
• Asmanex
• Singulair
• Xolair
• Cinquil
• Mepolizumab
• Benralizumab
• Lebrikizumab
• Dupilumab
• Advair/Seretide
• Symbicort
• Combivent
• Dulera
• Breo/Relvar Ellipta

See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:
• US
• Japan
• EU5
• BRIC
• Mexico

Asthma and COPD Therapies Market Forecast 2015-2025 Opportunities for Leading Companies

Leading companies and potential for market growth
Overall revenue for the Asthma and COPD Therapies market will reach $35.87in 2019, our work forecasts. We predict strong revenue growth through to 2025. An ageing population and increasing incidence of respiratory diseases globally will drive sales to 2025.

Our work analyses the key companies in the market. See Visiongain’s analysis of 7 leading companies, including these:
• GSK
• Boehringer Ingelheim
• AstraZeneca
• Merck
• Novartis
• Roche
• Teva

A company profile gives you the following information where available:
• 10 year revenue forecast for respiratory products with annual growth rates
• Discussion of a company’s activities and outlook
• Analysis of products currently on the market as well as those in the pipeline

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the Asthma and COPD Therapies industry?
Our new report discusses issues and events affecting the Asthma and COPD Therapies market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of national markets
• Patent expiry challenging major market players
• Emerging areas of therapies with potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Asthma and COPD Therapies Market Forecast 2015-2025 report helps you
In summary, our 309-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the asthma and COPD therapies market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for submarkets and leading therapies in each – discover prospects for leading drugs in the following asthma and COPD submarkets: bronchodilator monotherapy (including SABAs, LABAs and anticholinergics), anti-inflammatory drugs (including corticosteroids, anti-leukotrienes and monoclonal antibodies) and combination drugs
• Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5, BRIC and Mexico
• Assessment of 7leading companies – analysis of respiratory revenues, products and pipeline
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Asthma and COPD therapies market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies Market Forecast 2015-2025


Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies Market Forecast 2015-2025


Latest Pharma news

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

READ

Visiongain Publishes Antigen Skin Test Market Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.

12 January 2021

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.

11 January 2021

READ

Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.

11 January 2021

READ

Categories

Category